OAB and Incontinence

OnabotulinumtoxinA (Botox) appears to increase the activity of brain regions involved in sensation and processing of urinary urgency in female patients with neurogenic overactive bladder, says Rose Khavari, MD.

Among 321 scheduled telemedicine visits for patients with neurogenic bladder, the compliance rate was 91%.

Analyses with patients stratified into three groups by age showed that an emulsified microdose desmopressin acetate nasal spray (Noctiva) consistently extended the first uninterrupted sleep period in a clinically meaningful manner for patients of all ages.

“Unless there’s a contraindication, they have to try medications. ‘I don’t feel like taking it’ is not failing a medication,” says one urologist.

Attorneys will scour for online ‘dirt’ to use in a lawsuit, writes Brianne Goodwin, JD, RN.

Modifier use without supporting documentation could be considered fraudulent, write Ray Painter, MD, and Mark Painter.

Data from a recent study also indicate that overactive bladder patients discontinue pharmacotherapy long-term despite chronic symptoms.

Until now there has been no large, thorough investigation into the risk of clean intermittent catheterization in patients undergoing repeat injections of onabotulinumtoxinA.

"Concerns about scope of practice aside, there is no doubt that as the demand for urologic services increases and the number of practicing urologists decreases, we will need to find alternative ways to continue to see and treat our patients," writes Henry Rosevear, MD.

The oral beta-3 agonist vibegron, taken once daily at either 50 mg or 100 mg, is well tolerated and results in clinically and statistically significant reductions in daily micturitions, urge incontinence, and urgency episodes.

A nickel-sized leadless titanium device, implanted in patients’ ankles, could provide years of relief from overactive bladder syndrome.

In this article, we review the underlying causes of nocturia and outline an approach to its diagnostic evaluation and treatment.

Researchers have reported an association with the release of the AUA/SUFU Adult Urodynamics Guideline and reduction of urodynamics performed for diagnosis of overactive bladder, stress urinary incontinence, and mixed urinary incontinence.

General urologists are less likely to utilize third-line interventions for overactive bladder than those with additional female pelvic medicine and reconstructive surgery training.

The physician argued that the migration of the mesh is a known risk of the procedure and the patient had given informed consent for the operation.

"It’s absolutely important. Because we have so much overlap in our patient population, our patients are best served by us working together," says one urologist.

In patients with refractory urgency urinary incontinence (UUI), sacral neuromodulation (InterStim) and onabotulinumtoxinA (Botox) produce similar reductions in mean daily UUI episodes, according to 24-month follow-up data on patients treated in a randomized trial.

New research may pave the way for a form of nerve stimulation for refractory overactive bladder that is home based and less invasive than current neuromodulation approaches.

A study that found that age was more strongly associated with selection of colpocleisis than frailty and a comparison of two common wide pore polypropylene Y meshes were among the noteworthy female urology/incontinence research at the AUA annual meeting in Boston.

Urology Times reached out to three urologists (selected randomly) and asked them each the following: Are anticholinergic drugs overused in treating OAB?

In this interview, Sarah E. McAchran, MD, discusses the need for urology-gynecology collaboration, the background behind the ABMS recognizing the female pelvic medicine and reconstructive surgery subspecialty, and how barriers to full integration of providers treating pelvic floor disorders can be overcome.

For most of her life, former Olympic gymnast Mary Lou Retton suffered from severe urgency and frequency related to overactive bladder. It wasn't until she consulted a urologist just over a year ago that Retton, now 37, received relief from her sometimes debilitating symptoms.Retton has gone public with her personal struggle in a campaign backed by Pfizer. She said she hopes her own experience will help others with the condition seek proper care.